MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation DSO Ratio 2011-2026 | NEOG
Annual DSO Ratio Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.6 | 64.4 | 56.1 | 66.3 | 68.8 | 73 | 72.8 | 71.8 | 69.2 | 76.9 | 76.3 | 76.6 | 68.1 | 70.7 | 60.5 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 76.9 | 56.1 | 69.2 |
Quarterly DSO Ratio Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.9 | 63.6 | - | 66.9 | 65.5 | 71.6 | - | 64.6 | 57.3 | 58 | - | 60.4 | 46.8 | 66.5 | 24.3 | 66 | 62.9 | 63.7 | 32.4 | 67.1 | 62.5 | 67.8 | 65.6 | 75.9 | 69.6 | 72.7 | 69.9 | 74.2 | 68.3 | 72 | 67.4 | 73.2 | 63.3 | 64.6 | 31.8 | 68.9 | 62.5 | 69.3 | 68 | 68.3 | 66.8 | 72.1 | 67.9 | 67.8 | 69.2 | 69.9 | 69.2 | 65.9 | 68.5 | 64.2 | 59.3 | 59.5 | 67.7 | 67.3 | 64.1 | 62 | 65.6 | 61.2 | 58.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 75.9 | 24.3 | 63.8 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
|
Biodesix
BDSX
|
41.7 | $ 15.79 | 4.78 % | $ 2.05 B |  USA |
 |
Agilent Technologies
A
|
63.8 | $ 115.15 | -0.26 % | $ 35 B | USA |
 |
Biomerica
BMRA
|
57.7 | $ 2.15 | -1.15 % | $ 4.94 M | USA |
 |
BioNano Genomics
BNGO
|
63.7 | $ 1.16 | -3.75 % | $ 6.32 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
31.7 | $ 16.25 | 0.28 % | $ 175 M |  China |
 |
CareDx, Inc
CDNA
|
51.5 | $ 18.22 | -0.49 % | $ 971 M | USA |
 |
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
94.7 | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 167.39 | -3.74 % | $ 8.3 B | USA |
 |
Castle Biosciences
CSTL
|
49.2 | $ 25.23 | 1.57 % | $ 701 M | USA |
 |
Danaher Corporation
DHR
|
55.3 | $ 192.1 | 0.51 % | $ 137 B | USA |
 |
DexCom
DXCM
|
87 | $ 63.05 | 1.33 % | $ 24.6 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 16.55 | -1.61 % | $ 500 M | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Guardant Health
GH
|
46.1 | $ 90.82 | -3.21 % | $ 11.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 111.31 | -2.52 % | $ 9.18 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
66.9 | $ 1.92 | -1.92 % | $ 8.49 M | USA |
 |
Illumina
ILMN
|
61.3 | $ 127.58 | 0.15 % | $ 20.3 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 170.35 | -1.67 % | $ 29.3 B | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 274.41 | 0.22 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
80.5 | $ 75.97 | -0.17 % | $ 5.13 B | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 495.2 | -0.63 % | $ 14.3 B | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 263.66 | 0.3 % | $ 26 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.79 | 0.74 % | $ 444 M | USA |
 |
ENDRA Life Sciences
NDRA
|
7.11 | $ 4.56 | -2.72 % | $ 3.59 M | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 7.99 | -0.13 % | $ 1.02 B | USA |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.52 | 2.07 % | $ 392 M | USA |
 |
Natera
NTRA
|
81.5 | $ 205.75 | -1.07 % | $ 20.2 B | USA |
 |
Pacific Biosciences of California
PACB
|
71.8 | $ 1.41 | 4.85 % | $ 423 M | USA |
 |
Precipio
PRPO
|
21.1 | $ 26.16 | 2.35 % | $ 42 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 6.62 | 0.53 % | $ 392 M | USA |
 |
RadNet
RDNT
|
34.5 | $ 55.4 | 1.11 % | $ 4.17 B | USA |
 |
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | USA |
 |
Senseonics Holdings
SENS
|
10.3 | $ 6.93 | 0.36 % | $ 289 M | USA |